Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clofarabine + cyclophosphamide
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of clofarabine and cyclophosphamide. This combination demonstrates synergistic antileukemic effects, primarily used for treating relapsed or refractory acute leukemias in pediatric patients. Clofarabine inhibits DNA polymerase \u03b1 and ribonucleotide reductase, disrupts mitochondrial membrane integrity leading to programmed cell death, and inhibits DNA repair. Cyclophosphamide is an alkylating agent that cross-links DNA via active metabolites. The combination shows enhanced efficacy because clofarabine potentiates cyclophosphamide's activity by inhibiting the repair of cyclophosphamide-induced DNA damage.
- Other names
- Clofarabine and CyclophosphamideClofarabine plus Cyclophosphamide
02
Targets
DNAPOLA1 (DNA polymerase alpha)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on clofarabine + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clofarabine + cyclophosphamide.